A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PROOF OF CONCEPT STUDY ASSESSING THE EFFICACY AND SAFETY OF THE RIPK1-INHIBITOR SAR443122 IN PATIENTS WITH MODERATE TO SEVERE SUBACUTE OR DISCOID/CHRONIC CUTANEOUS LUPUS ERYTHEMATOSUS

Registry ID

ACT16404

Source registry

HEALTH_CANADA

Status

Ongoing

Study type

INTERVENTIONAL

Sponsor

SANOFI-AVENTIS CANADA INC

Start date

2021-03-10

Last update

2021-02-12

Conditions

• SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS
• DISCOID LUPUS ERYTHEMATOSUS

Related clinical trials

• A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND EFFICACY OF IMVT-1402 IN PARTICIPANTS WITH ACTIVE SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE) AND/OR CHRONIC CUTANEOUS LUPUS ERYTHEMATOSUS (CCLE) WITH OR WITHOUT SYSTEMIC MANIFESTATIONS
• A PHASE 2, SINGLE-BLIND, INTRAINDIVIDUAL STUDY TO EVALUATE THE EFFICACY OF RUXOLITINIB 1.5% CREAM IN ADULT SUBJECTS WITH DISCOID LUPUS ERYTHEMATOSUS
• A 2-PART SEAMLESS PART A (PHASE 2)/PART B (PHASE 3) RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIIB059 IN PARTICIPANTS WITH ACTIVE SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS AND/OR CHRONIC CUTANEOUS LUPUS ERYTHEMATOSUS WITH OR WITHOUT SYSTEMIC MANIFESTATIONS AND REFRACTORY AND/OR INTOLERANT TO ANTIMALARIAL THERAPY (AMETHYST
• A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLELGROUP TRIAL TO INVESTIGATE THE EFFICACY AND SAFETY OF DAXDILUMAB SUBCUTANEOUS INJECTION IN REDUCING DISEASE ACTIVITY IN ADULT PARTICIPANTS WITH MODERATE-TOSEVERE PRIMARY DISCOID LUPUS ERYTHEMATOSUS

View on source registry